Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells

CONCLUSION: This study reveals the potent antitumor activity of BVD-523 against thyroid cancer cells bearing MAPK-activating mutations, offering promise for treating aggressive forms of thyroid cancer.PMID:38687926 | DOI:10.4103/jcrt.jcrt_1504_23

Source: Cell Research - April 30, 2024 Category: Cytology Authors: Yulu Chen Xi Xiao Guanghui Hu Rengyun Liu Junyu Xue Source Type: research